## Recurrent stroke: the role of thrombophilia in a large international pediatric stroke population

Gabrielle deVeber,<sup>1</sup>\* Fenella Kirkham,<sup>2,3</sup>\* Kelsey Shannon,<sup>1</sup> Leonardo Brandão,<sup>1</sup> Ronald Sträter,<sup>4</sup> Gili Kenet,<sup>5</sup> Hartmut Clausnizer,<sup>6</sup> Mahendranath Moharir,<sup>1</sup> Martina Kausch,<sup>6</sup> Rand Askalan,<sup>1</sup> Daune MacGregor,<sup>1</sup> Monika Stoll,<sup>7</sup> Antje Torge,<sup>6</sup> Nomazulu Dlamini,<sup>1</sup> Vijeja Ganesan,<sup>2</sup> Mara Prengler,<sup>2</sup> Jaspal Singh<sup>3</sup> and Ulrike Nowak-Göttl<sup>4/6</sup>

<sup>1</sup>The Hospital for Sick Children, Toronto, Canada; <sup>2</sup>Developmental Neurosciences Programme, UCL Great Ormond Street Institute of Child Health, London, UK; <sup>3</sup>University Hospital Southampton, UK; <sup>4</sup>Department of Paediatric Haematology/Oncology, University of Münster, Münster, Germany; <sup>5</sup>Pediatric Coagulation Service, National Hemophilia Centre and Institute of Thrombosis and Hemostasis Sheba Medical Center, Tel-Hashomer, Israel; <sup>6</sup>Institute of Clinical Chemistry, University Hospital Kiel-Lübeck, Kiel, Germany and <sup>7</sup>Department of Genetic Epidemiology, University of Münster, Münster, Germany

\*GdeV and FK contributed equally to this work.

doi:10.3324/haematol.2019.234666

©2019 Ferrata Storti Foundation

In the article pre-published online on January 24, 2019 and published in the paper version of Haematologica [volume 104(8):1676-1681; doi:10.3324/haematol2018.211433] we have to correct:

> that recurrent stroke occurred in 160/872 (instead of 160 / 880) children [page 1678, second column, line 6].

> the incidence rates of recurrent AIS with respect to the individual exposure time in years given in the abstract (page 1676, lines 16-18) and in the results section (page 1679, paragraph "prothrombotic risk factors", lines 38-40). As explained in the methods section, we calculated the absolute risk of AIS recurrence as incidence rates per 100 patient-years (%). According to the individual exposure times (years) to antithrombin, lipoprotein (a) and the presence of more than one prothrombotic risk factor the **incidence rates calculated per 100 patient-years** are presented in the table below.

Type of thrombophilia	Exposure time (years)	Event (n)	Incidence per 100 patient-years % (95% CI)
Antithrombin deficiency	2437	7	0.3 (0.1-0.6)
Elevated lipoprotein(a)	1938	23	1.2 (0.7-1.7)
More than one prothrombotic risk factor	2887	23	0.8 (0.5-1.1)

CI: Confidence interval: n: number